Mary Kay Fenton

Insider Reports History

Location
Achillion Pharmaceuticals, 300 George Street, New Haven, CT
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Mary Kay Fenton:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Talaris Therapeutics, Inc. Chief Financial Officer Common Stock 68.1K $1.16M $16.99 Jul 3, 2023 Direct
Cullinan Therapeutics, Inc. Chief Financial Officer Common Stock 60K $751K $12.51 Feb 19, 2025 Direct
Talaris Therapeutics, Inc. Chief Financial Officer Stock Appreciation Right 150K Feb 1, 2023 Direct
Talaris Therapeutics, Inc. Chief Financial Officer Stock Option (Right to Buy) 150K Feb 1, 2023 Direct
Cullinan Therapeutics, Inc. Chief Financial Officer Stock Option (Right to Buy) 120K Feb 19, 2025 Direct
Oncorus, Inc. Director Stock Option (right to buy) 12.5K Jun 23, 2022 Direct

Insider Reports Filed by Mary Kay Fenton

Symbol Company Period Transactions Value $ Form Type Date Filed Role
CGEM Cullinan Therapeutics, Inc. Feb 19, 2025 2 $0 4 Feb 21, 2025 Chief Financial Officer
CGEM Cullinan Therapeutics, Inc. Apr 29, 2024 1 $0 4 Apr 30, 2024 Chief Financial Officer
CGEM Cullinan Therapeutics, Inc. Apr 29, 2024 0 $0 3 Apr 30, 2024 Chief Financial Officer
TALS Talaris Therapeutics, Inc. Jul 3, 2023 1 -$39.9K 4 Jul 6, 2023 Chief Financial Officer
TALS Talaris Therapeutics, Inc. Feb 1, 2023 2 $0 4 Feb 3, 2023 Chief Financial Officer
TALS Talaris Therapeutics, Inc. Sep 10, 2022 1 $0 4 Sep 13, 2022 Chief Financial Officer
ONCR Oncorus, Inc. Jun 23, 2022 1 $0 4 Jun 24, 2022 Director
TALS Talaris Therapeutics, Inc. Feb 1, 2022 2 $13K 4 Feb 2, 2022 Chief Financial Officer
ONCR Oncorus, Inc. Jun 16, 2021 1 $0 4 Jun 17, 2021 Director